Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...

Cipla finished the day at Rs 1420.55, showing a fall of 1.32% in its market value. Cipla's shares are currently priced at Rs 1416.6, down by 1.6% today, and it has a beta of 0.551 for the past six ...

Cipla share price today: The pharma major reported a 49% increase in net profit, reaching Rs 1,571 crore (Image: Reuters) Motilal Oswal has maintained a Neutral rating on Cipla, with a target ...

Cipla's North American business achieved a record $250 million revenue in Q1 FY25, a 13% year-on-year growth. The company's branded prescription business in India grew 10%, while overall India growth ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

For the first nine months of FY25, Cipla's EBITDA margin stood at 26.9%, already above its full-year guidance of 24.5% to 25.5%.

At the awards night, Cipla took home a total of 4 metals across categories for its impressive work and creativity. The brand won 2 silver and 2 bronze metals across categories. Apart from Cipla ...

CIPLA delivered better-than-expected 3QFY25 earnings. While revenue was in line, EBITDA/adj. PAT beat our estimates, aided by a better product mix and lower R&D spending. Among the segments, CIPLA ...

Revenue 25,774.09 22,753.12 21,763.34 19,159.59 ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...